Article

Atractylenolide I ameliorated the progression of CRPC by suppressing KIF15/AR/AR-V7 signaling

2023-09-04

Abstract excerpt

<h4>Background: </h4> and purpose: Castration-resistant prostate cancer (CRPC) has been a major cause of tumor-associated death among men worldwide. The discovery of novel therapeutic approaches for CRPC remains imperative. Atractylenolide I (ATR-I), a prominent bioactive component from Atractylodes macrocephala, exhibits powerful anticancer potentials in various malignancies. Nevertheless, the ATR-I’s activity on...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 46ca2dac-6df1-5ed7-9ddf-5e0af170b612
DOI: 10.22541/au.169381156.62145490/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Atractylenolide I ameliorated the progression of CRPC by suppressing KIF15/AR/AR-V7 signalingDOI 10.22541/au.169381156.62145490/v1Read

The mechanistic role of long non-coding RNAs in advanced prostate cancer response to therapySemantic proximity Read

CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration- resistant prostate cancer by bioinformatic analysisSemantic proximity Read

Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivoSemantic proximity Read

Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivoSemantic proximity Read

Progress in the mechanism and drug development of castration-resistant prostate cancer.Semantic proximity Read

Exploration and Identification of Potential Therapeutic Targets and Biomarkers for Docetaxel Resistant Prostate CancerSemantic proximity Read

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancerSemantic proximity Read

Inhibition of Galectin-1 and androgen receptor axis enhances enzalutamide treatment in enzalutamide resistant prostate cancerSemantic proximity Read

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerSemantic proximity Read

SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBsSemantic proximity Read

Clofazimine treatment modulates key non-coding RNAs associated with tumor progression and drug resistance in lethal Prostate CancerSemantic proximity Read